AWA
NVCR icon

Authentikos Wealth Advisory’s NovoCure NVCR Stock Holding History

Authentikos Wealth Advisory’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-30
Closed -$485 – 402
2023
Q3 		$485 Buy
+30
New +$865 ﹤0.01% 572

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Authentikos Wealth Advisory's NVCR Position: Q4 2023 in Review

Authentikos Wealth Advisory sold out of NovoCure (NVCR) in Q4 2023, closing a stake of 30 shares — an estimated $485 sold.

Authentikos Wealth Advisory first reported a position in NVCR in Q3 2023 and held it in 1 quarter. The position peaked at $485 in Q3 2023. 219 funds tracked by Wall St. Rank hold NVCR as of Q4 2023.

  • Authentikos Wealth Advisory reported no remaining NovoCure position as of Q4 2023 after selling out during the quarter.
  • Authentikos Wealth Advisory sold 30 NovoCure shares in Q4 2023, an estimated $485.
  • Authentikos Wealth Advisory first reported a position in NovoCure in Q3 2023 and held it in 1 quarter.
  • Authentikos Wealth Advisory's NovoCure position peaked at $485 in Q3 2023.
  • 219 funds tracked by Wall St. Rank held NovoCure as of Q4 2023.

Based on Authentikos Wealth Advisory's 13F filing for Q4 2023, filed 30 Jan 2024.